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The most effective management strategy for viral infections 
is prevention through vaccines, as reported in a pilot study of her-
pes zoster vaccination in 10 adult SLE patients older than 50 years 
of age,12 but the efficacy and safety of this live-attenuated virus 
vaccine in a large SLE population is unknown.
In conclusion, lupus in children has a higher susceptibility to 
HZI and is characterized by a shorter disease duration, disease activ-
ity and lower frequency of postherpetic neuralgia than in adults with 
SLE. Both groups have a comparable and good overall outcome.
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Abstract: Human rhinoviruses (HRV) cause respiratory infections and are 
associated with asthma development. We assessed HRV prevalence, types 
and association with respiratory symptoms in the first year of life in 20 
unselected infants. HRV was detected in 32% of 825 weekly nasal swabs. 
Seventy-four different types of all three species were identified. HRV pres-
ence and related respiratory symptoms are highly heterogeneous. 
Key Words: rhinovirus, respiratory tract infection, infant, birth cohort 
Accepted for publication February 9, 2105. 
From the *University Children’s Hospital (UKBB), University of Basel, Basel, 
Switzerland; †Pediatric Respiratory Medicine, Inselspital and University of 
Bern, Bern, Switzerland; ‡Laboratory of Virology, Division of Infectious 
Diseases, University Hospitals of Geneva, Faculty of Medicine, Geneva, 
Switzerland; and §Department of Clinical Research, University of Bern, 
Bern, Switzerland.
This study was supported by the Swiss National Foundation (SNF; grants 
324730_144280/1 and 32473B_146679) and the Botnar Foundation Swit-
zerland. The authors have no conflicts of interest to disclose.
Address for correspondence: Loretta Müller, PhD, University Children’s  Hospital 
Basel (UKBB), Spitalstrasse 33, 4031 Basel, Switzerland. E-mail: loretta.
mueller@ukbb.ch
Supplemental digital content is available for this article. Direct URL citations 
appear in the printed text and are provided in the HTML and PDF versions of 
this article on the journal’s website (www.pidj.com).
Human rhinoviruses (HRV) are the most common respiratory viruses identified in humans with respiratory infections,1 and 
they play a major role in respiratory morbidity of children.2,3 HRV-
induced wheezing during early life is strongly associated with the 
later development of asthma.4 Based on their genetic divergence, 
HRVs are divided into 3 species: HRV-A, HRV-B and HRV-C, 
of which HRV-A and HRV-C are thought to cause most severe 
 symptoms.5 For each HRV species, various types are known.
Despite the high frequency of HRV infections, detailed 
information is lacking on prevalence of HRV types and their asso-
ciation with presence and severity of respiratory symptoms, espe-
cially in early infancy of otherwise healthy children. Therefore, 
we analyzed weekly nasal swabs for HRV presence, sequenced 
positive samples for HRV typing and compared the results with 
respiratory symptoms.
METHODS
In a subsample of 20 healthy infants (9 female, 11 male) 
nested in the prospective Basel–Bern-Infant-Lung-Development 
cohort study,6 we analyzed the presence of HRV RNA by one-
step real-time polymerase chain reaction in nasal swabs collected 
weekly during the first year of life. HRV-positive samples were fur-
ther sequenced to determine HRV types (for method see Tapparel et 
al7). Signs of respiratory symptoms (cough, wheeze and breathing 
difficulties) were assessed based on a standardized symptom score 
by weekly telephone interviews with the parents.6 The study was 
approved by the Ethics Committee Bern, Switzerland and written 
informed consent was obtained from the parents.
RESULTS
Prevalence of HRV Species and Types
HRV was detected in 266 of 831 nasal swabs (32%). HRV-A 
and HRV-C were almost equally frequent (38% and 39%, respec-
tively), followed by HRV-B (12%). Ten percent of the samples were 
untypable (because of poor sample quality or undetectable viral 
load). In total, 74 different HRV types were identified (30 HRV-
A, 8 HRV-B and 36 HRV-C). Twelve HRV types of all 3 species 
were particularly frequent and found in 5 or more samples: A78 
(detected in 17 samples), A16 (in nine samples), B6 (in 8 samples), 
A56, A89 (both in 7 samples), A101, C1, C9 (all in 6 samples), 
A12, C22, C26 and C39 (all in 5 samples). Those HRV types were 
identified in samples of 1 (A12), 3 (B6, A89, C1), 4 (A16, A56, 
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C22, C26, C39), 5 (C9), 6 (A101) or 7 (A78) infants (for details 
see Fig., Supplemental Digital Content 1, http://links.lww.com/
INF/C142). The infective period lasted between 1 and 5 positive 
samples based on our weekly sampling. The seasonal prevalence of 
the 3 HRV species was not different. In total, we detected 55 HRV-
positive samples during spring (March–May), 68 during summer, 
74 during fall and 31 during winter months.
Association of HRV Prevalence and Respiratory 
Symptoms
In total, half of HRV-positive episodes were accompanied by 
respiratory symptoms, with slight differences among species: 53% 
of HRV-A [95% confidence interval (CI) = 42–63%], 42% of HRV-B 
(CI = 25–61) and 51% of HRV-C (CI = 40–61) positive episodes were 
symptomatic (Fig., Supplemental Digital Content 1, http://links.lww.
com/INF/C142). Wheezing was reported 11 times in the context of 
HRV detection with the types A40, A56, A101, C1, C9, C28 and C40. 
The 3 most frequently detected types (A78, A16, B6) were sympto-
matic in 53%, 75% and 75% of the HRV-positive samples, respectively. 
Overall, the association between HRV types and respiratory symptoms 
was highly heterogeneous without any recognizable pattern.
DISCUSSION
During the first year of life of 20 unselected infants, we found 
74 different HRV types of all 3 HRV species. We found HRV-A and 
HRV-C almost equally often and fewer HRV-B. Despite differences in 
study design and sampling procedure this distribution is similar to those 
found by others.5,8 Others have studied the presence of HRV in nasal 
lavages during scheduled and unscheduled sick visits from otherwise 
healthy infants of a high-risk birth cohort study5 or the presence of 
rhinoviruses in nose–throat swabs of healthy children <5 years with 
symptoms of an acute respiratory illness.8 We are thus confident that 
our results are also representative of other populations of this age group.
The lower detection frequency of HRV-B is either because 
of lower prevalence (32 HRV-B types identified vs. 80 HRV-A and 
54 HRV-C) or its different virus characteristics. Nakagome et al9 
recently showed that HRV-B types isolated from clinical samples 
have lower replication rates in differentiated primary epithelial 
cells compared with HRV-A and HRV-C types.
Each infant in our study had at least 9 HRV-positive samples 
and 4 different HRV types identified during her or his first year of 
life. In total, we found 74 different HRV types  showing a high vari-
ability and dynamic pattern of HRV. The lack of a clear association 
between specific HRV types and respiratory symptoms might relate 
to this high variability and/or other factors influencing respiratory 
symptoms (eg, concomitant pathogens, such as bacteria or other 
respiratory viruses, or individual immune responses).
The strengths of our study are an unbiased selection of the 
infants and the weekly sampling, including assessment of respira-
tory symptoms. Mothers were recruited before birth and infants 
were not selected based on health problems or respiratory symp-
toms giving a completely unbiased view on HRV presence in early 
infancy. Despite the large sample size of 831 samples and because 
of the high number of different HRV types, no pattern for associa-
tion of HRV types with respiratory symptoms was detected. Thus 
even larger studies seem to be necessary to draw firm conclusions 
on respiratory symptoms induced by particular HRV types.
We confirm data from other studies5,10 showing that the HRV 
population in the human airway is highly dynamic and rapidly 
FIGURE 1. Presence of HRV in nasal swabs during the first year of life of 20 children. Arrows stand for sampling start; full 
upright lines indicate presence of respiratory symptoms, and half upright lines indicate that no symptoms were present in that 
particular week; squares show infection with HRV-A, circles infection with HRV-B, hexagons infection with HRV-C and rhombus 
infections with enterovirus 68. × shows infection with an untypable HRV type; stars indicate reported wheezing; f stands for 
female and m for male infants.
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changing. This means that in vitro studies using single lab strains 
indeed may add important mechanistic knowledge but never repre-
sent the complex in vivo situation.
For now, we conclude that the presence of different HRV 
species and types in the airways during infancy is highly het-
erogeneous and dynamic, that about half of the HRV infections 
in early life are not accompanied by respiratory symptoms and 
no clear association between HRV types in inducing respiratory 
symptoms exists. Each infant included in our study had at least 9 
HRV-positive samples and 4 different HRV types identified just 
during its first year of life. This shows that HRV infections and 
HRV-associated symptoms in early infancy, and their potential 
role in asthma development, are rather complex.
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Abstract: We reviewed all cases of Nocardia infection in cystic fibrosis 
patients at 2 centers. Eight of 200 patients had Nocardia in sputum. Four 
developed severe lung disease, including 3 with associated allergic bron-
chopulmonary aspergillosis; 4 remained clinically stable. Nocardia is often 
associated with significant lung disease in cystic fibrosis, possibly associ-
ated with allergic bronchopulmonary aspergillosis or steroids. 
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Nocardiosis in cystic fibrosis (CF) is possibly associated with increasing length of survival, chronic antibiotic therapy, a 
changing pulmonary microbiome or improving diagnosis.1
Pulmonary Nocardia infection in CF patients was first 
described 20 years ago. Its role as a causative agent for either acute 
or chronic pulmonary disease is debated, and a recent report sug-
gested that no treatment is required.1 In our experience, Nocardia 
infection in CF can sometimes lead to inexorable pulmonary dete-
rioration and even lung transplantation.
We did a retrospective chart review from 2002 through2013, 
at 2 CF centers in Israel: the Graub CF Center at Schneider Children’s 
Medical Center of Israel and the CF Center at Meyer Children’s Hos-
pital, Rambam Medical Center. All patients met the CF Foundation 
Consensus Panel criteria for CF diagnosis. Sputum was acquired at 
least twice annually for Ziehl–Neelsen staining and culture on blood 
agar for 3 weeks. If found positive, cultures were subsequently taken 
at every clinic visit, that is, every 1–2 months. We considered Nocar-
dia to be eradicated if 3 consecutive sputum cultures were negative.
The study was approved by the hospitals’ ethics committees.
RESULTS
We reviewed charts of 200 CF patients aged 2 months to 
63 years. Eight (4%) had at least 1 positive sputum culture for 
Nocardia. Findings are summarized in Table 1.
Two patterns of Nocardia infection were observed: 
(1) patients 1–4 experienced a complicated clinical course with res-
piratory deterioration leading to the decision to treat the infection; 
patients 1–3 also had pulmonary nodules consistent with Nocardia 
lung disease on chest computerized tomography (CT); (2) patients 
5–8 had a more gradual deterioration in their pulmonary disease. 
In patients 5 and 8, no other pathogens were identified despite pul-
monary symptoms. This led to the decision to treat the Nocardia. 
In patient 6, there was an associated decrease in lung function, 
which improved once Nocardia was eradicated. Only patient 7 had 
no treatment as there appeared to be no associated clinical decline.
When Nocardia was repeatedly cultured, with clinical symp-
toms but without an aggressive course, trimethoprim–sulfamethox-
azole (TMP/SMX) single drug therapy was instituted. In cases with 
a more fulminant clinical course, particularly when resistance to 
TMP/SMX was shown on susceptibility studies, multidrug therapy 
including intravenous (IV) meropenem or oral linezolid was insti-
tuted for several months.
Case Presentations
Patient 1, a 55-year-old female, was diagnosed with CF at 41 
years with diffuse bronchiectasis, recurrent major hemoptysis and 
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